智翔金泰(688443) - 2024 Q4 - 年度业绩预告

Revenue Expectations - The company expects 2024 annual revenue to be between 28.62 million and 31.64 million, an increase of 27.41 million to 30.43 million compared to the previous year, representing a year-on-year growth of 2262.72% to 2511.43%[2] - The significant revenue growth is primarily due to the commercial launch of the company's monoclonal antibody injection, which generated sales revenue, whereas the previous year had minimal revenue from technical services[6] R&D Expenses - The estimated R&D expenses for 2024 are projected to be between 560.48 million and 657.96 million, a decrease of 59.91 million to an increase of 37.56 million compared to the previous year, reflecting a year-on-year change of -9.66% to +6.05%[2] - The company maintains a high level of R&D investment as multiple products enter clinical research and core products reach critical clinical trial stages[6] Net Loss Projections - The expected net loss attributable to the parent company for 2024 is projected to be between -731.28 million and -858.46 million, a reduction of 70.04 million to an increase of 57.14 million compared to the previous year, indicating a year-on-year change of -8.74% to +7.13%[2] - The net loss attributable to the parent company after deducting non-recurring gains and losses is expected to be between -738.34 million and -865.52 million, with a year-on-year change of -9.18% to +6.47%[3] Financial Forecast Integrity - The financial data in this earnings forecast is based on preliminary calculations by the company's finance department and has not been audited by a registered accountant[7] - The company has not identified any major uncertainties that could affect the accuracy of this earnings forecast[7]